All News
KNOW YOUR NUMBERS! (2.10.2023)
Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on RheumNow.com.
Read Article
Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.
Read Article
Does Methotrexate Increase Skin Cancer Risk?
There are several reports suggesting a link between methotrexate (MTX) use and certain skin cancers, yet these are confounded by a higher risk of skin cancers with inflammatory conditions like rheumatoid arthritis of which MTX is the most common treatment.
Read Article
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active systemic lupus erythematosus (SLE).
Read Article
Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/ZU5wGXMDMC https://t.co/9kp20kfuCn
Links:
Dr. John Cush RheumNow ( View Tweet)
β-damascone, a major aroma from rose, was shown in animal models to dendritic cell -mediated immune functions, thusly demonstrating anti-inflammatory properties https://t.co/0w2b2dflkM https://t.co/zz0l7DJSY4
Links:
Dr. John Cush RheumNow ( View Tweet)
Know your numbers!!
Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on https://t.co/V10S4oVFsv.
https://t.co/xU0Ti4wwpq https://t.co/iQId9IDqHc
Dr. John Cush RheumNow ( View Tweet)
Serious Infection Risk in Pediatric Psoriasis with Ustekinumab, Etanercept, or MTX
This comparative analysis looks at the risk of SIE requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or MTX prior to 2016.
https://t.co/kR14nrZzCo https://t.co/ccFJcO0eAj
Links:
Dr. John Cush RheumNow ( View Tweet)
The FDA has added a new indication to the oral JAK inhibitor Cibinqo (abrocitinib) - now approved to treat atopic dermatitis in adolescents 12 to under 18 years old. (Approval is based on a phase 3 JADE TEEN trial. https://t.co/DsQj3BfPmZ https://t.co/0bpb2FAwpg
Links:
Dr. John Cush RheumNow ( View Tweet)
An open-label trial of 170 adults w/ IgA Nephropathy (proteinuria >1 g/d) evaluated addition of mycophenolate to standard care (SC). MMF (1.5g/d) associated w/ less renal worsening - 7.1% MMF + SC vs. 21% SC alone (aHR 0.23; 95% CI, 0.09-0.63) https://t.co/FlcafoZi3U https://t.co/tQkZE8RRyy
Links:
Dr. John Cush RheumNow ( View Tweet)
Meta-analysis (21 studies, 3948 pregnant pts) HCQ may reduce risk of preeclampsia (OR 0.45) & premature delivery (OR 0.84) in pregnant autoimmune pts. HCQ may also reduce risk of gestational HTN (OR 0.42) & pre-term birth (OR 0.63) in pregnant SLE pts https://t.co/riQDRN9r1A https://t.co/uR8Nem4Ndx
Links:
Dr. John Cush RheumNow ( View Tweet)
Benlysta granted Orphan Drug Designation by US FDA as potential Rx of systemic sclerosis, such status facilitates eval in rare diseases. GSK is planning a trial of belimumab for SSc-associated interstitial lung disease in the first half of 2023 https://t.co/kWItB7NEvn https://t.co/eVbQtKy98H
Links:
Dr. John Cush RheumNow ( View Tweet)
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://t.co/KTYn1kv3qO https://t.co/eWbvMSBLxm
Links:
Dr. John Cush RheumNow ( View Tweet)
211 Adult Crohn's pts w/ steroid-free remission >6mo on Combo infliximab & immunosuppressant either cont combo or W/D IFX or Immsup. 2-yr relapse rates: 14% Combo vs, 36% IFX vs 10% Immunosup. WD of IFX had 3.45-4.76 fold incr rsk of flare https://t.co/6EbM3Vx0Ei https://t.co/5ZOE2oxCl0
Links:
Dr. John Cush RheumNow ( View Tweet)
Did you have a chance to listen to last week's RheumNow podcast? Dr. Cush covers rheumatology news from the last week. Make sure to tune in before we release our next episode tomorrow!
https://t.co/uRRg2K2K1a https://t.co/MjWF3Zl05i
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatment failures studied in 718 RA pts
- csDMARDs D/Cs intolerance (22%), inefficacy (20%), acute Rxns (5%), severe infx(0.6%)
- bDMARDs D/Cs inefficacy (29%), intolerance (10%), acute Rxns (6%), severe infx (1.5%)
- Multi-drug ifailure 5.7-8.4% https://t.co/FdoP77uELe https://t.co/dQjTNncABc
Links:
Dr. John Cush RheumNow ( View Tweet)
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/PjTQNHhduB https://t.co/m0erNXMkUC
Links:
Dr. John Cush RheumNow ( View Tweet)
GRAPPA Recommendations for Treating Enthesitis in PsA
GRAPPA has provided new updates to the mgmt of enthesitis in patients with PsA, affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
https://t.co/AC6KHGMeo0
Links:
Dr. John Cush RheumNow ( View Tweet)
New 5 Peptide Autoantibody Panel Complements RA Diagnosis
Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.
https://t.co/twgULvokPY https://t.co/O0I4i81RAN
Links:
Dr. John Cush RheumNow ( View Tweet)
Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3 with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, and calcinosis (but not renal crisis, ILD, or pulmonary HTN
https://t.co/Usrfr0XcCJ https://t.co/pmwkHsaJOx
Links:
Dr. John Cush RheumNow ( View Tweet)